Evidence map›Paper›PMID 32677994›Full record

ReviewJournal of hematology & oncology2020

Role of CD47 in Hematological Malignancies.

Entsar Eladl, Rosemarie Tremblay-LeMay, Nasrin Rastgoo, Rumina Musani, Wenming Chen, Aijun Liu, Hong Chang

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of hematology & oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 101 papers.

0numbers the graph read from it
0cells of the map it votes in
101citing papers in PubMed
6.9field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

101 citing papers in PubMed, 160 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Review

41 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Entsar EladlLaboratory Medicine Program, Toronto General Hospital, University Health Network, University of Toronto, 11th floor, 200 Elizabeth Street, Toronto, ON, M5G 2C4, Canada.
Rosemarie Tremblay-LeMayLaboratory Medicine Program, Toronto General Hospital, University Health Network, University of Toronto, 11th floor, 200 Elizabeth Street, Toronto, ON, M5G 2C4, Canada.
Nasrin RastgooLaboratory Medicine Program, Toronto General Hospital, University Health Network, University of Toronto, 11th floor, 200 Elizabeth Street, Toronto, ON, M5G 2C4, Canada.
Rumina MusaniLaboratory Medicine Program, Toronto General Hospital, University Health Network, University of Toronto, 11th floor, 200 Elizabeth Street, Toronto, ON, M5G 2C4, Canada.
Wenming ChenDepartment of Hematology, Beijing Chaoyang Hospital, Capital University, Beijing, China.
Aijun LiuDepartment of Hematology, Beijing Chaoyang Hospital, Capital University, Beijing, China. aijun.liu72@yahoo.com.
Hong ChangLaboratory Medicine Program, Toronto General Hospital, University Health Network, University of Toronto, 11th floor, 200 Elizabeth Street, Toronto, ON, M5G 2C4, Canada. hong.chang@uhn.ca.ORCID 0000-0003-3106-2776
University Health Network · CABeijing Chao-Yang Hospital, Capital Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

CD47, or integrin-associated protein, is a cell surface ligand expressed in low levels by nearly all cells of the body. It plays an integral role in various immune responses as well as autoimmunity, by sending a potent "don't eat me" signal to prevent phagocytosis. A growing body of evidence demonstrates that CD47 is overexpressed in various hematological malignancies and its interaction with SIRPα on the phagocytic cells prevents phagocytosis of cancer cells. Additionally, it is expressed by different cell types in the tumor microenvironment and is required for establishing tumor metastasis. Overexpression of CD47 is thus often associated with poor clinical outcomes. CD47 has emerged as a potential therapeutic target and is being investigated in various preclinical studies as well as clinical trials to prove its safety and efficacy in treating hematological neoplasms. This review focuses on different therapeutic mechanisms to target CD47, either alone or in combination with other cell surface markers, and its pivotal role in impairing tumor growth and metastatic spread of various types of hematological malignancies.

Indexed as

Molecular Targeted TherapyAngiogenic ProteinsAnimalsAntibodies, Monoclonal, HumanizedAntigens, DifferentiationAntineoplastic Agents, ImmunologicalCD47 AntigenClinical Trials as TopicDrug Delivery SystemsDrug DesignDrug Screening Assays, AntitumorHematologic NeoplasmsHumansIntegrinsLeukemiaLymphoma, Non-HodgkinAngiogenic ProteinsAntibodies, Monoclonal, HumanizedAntigens, DifferentiationAntineoplastic Agents, ImmunologicalCD47 AntigenCD47 protein, humanIntegrinsNeoplasm ProteinsOligopeptidesReceptors, ImmunologicSIRPA protein, humanCD47Hematological cancersImmunotherapyTargeted therapy

Identifiers

PMID32677994
PMCPMC7364564
OpenAlexW3042954004

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.